AAPG

Ascentage Pharma Group International ADR

16.90

Aug 26 • 3:59 PM ET +0.11 (0.66%)

16.94

Aftermarket • 7:30 PM ET +0.04 (0.24%)

Healthcare Biotechnology China Small NASD

Peers: TNGX CGON KYMR BMRN CRNX RYTM APGE INCY KRYS AXSM

Scroll to Statements

Index	-
Market Cap	1.57B
Enterprise Value	1.60B
Income	-210.51M
Sales	91.82M
Book/sh	0.88
Cash/sh	3.01
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	767
IPO	Jan 27, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	17.11
P/B	19.16
P/C	5.62
P/FCF	-
EV/EBITDA	-
EV/Sales	17.44
Quick Ratio	1.18
Current Ratio	1.22
Debt/Eq	3.76
LT Debt/Eq	1.11
Option/Short	No / Yes

EPS (ttm)	-2.26
EPS next Y	-0.38
EPS next Q	-0.36
EPS this Y	36.70%
EPS next Y	70.57%
EPS next 5Y	41.71%
EPS past 3/5Y	0.80% -1.32%
Sales past 3/5Y	36.88% 113.42%
EPS Y/Y TTM	-12.46%
Sales Y/Y TTM	69.80%
EPS Q/Q	-
Sales Q/Q	-
Earnings	Aug 18 AMC
EPS/Sales Surpr.	-490.95% -16.37%

Insider Own	-
Insider Trans	-
Inst Own	0.02%
Inst Trans	0.74%
ROA	-46.64%
ROE	-240.66%
ROIC	-121.48%
Gross Margin	83.18%
Oper. Margin	-220.00%
Profit Margin	-229.27%
SMA20	-4.84%
SMA50	-6.73%
SMA200	-28.86%
Trades

Shs Outstand	52.23M
Shs Float	-
Short Float	-
Short Ratio	1.25
Short Interest	0.01M
52W High	43.45 -61.10%
52W Low	16.36 3.30%
Volatility	3.86% 2.86%
ATR (14)	0.64
RSI (14)	39.05
Beta	0.07
Rel Volume	0.43
Avg Volume	11.39K
Volume	4,874

Perf Week	-6.27%
Perf Month	-7.57%
Perf Quarter	-19.14%
Perf Half Y	-32.53%
Perf YTD	-35.59%
Perf Year	-60.46%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	46.75
Prev Close	16.79
Price	16.90
Change %	0.66%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-10-26	Initiated	B. Riley Securities	Buy	$45
Apr-24-26	Initiated	Deutsche Bank	Buy	$40
Mar-12-26	Resumed	BTIG Research	Buy	$48
Jan-13-26	Initiated	Rodman & Renshaw	Buy	$48
Dec-04-25	Initiated	Oppenheimer	Outperform	$45
Nov-24-25	Initiated	Truist	Buy
Nov-10-25	Initiated	BTIG Research	Buy	$50
Nov-05-25	Initiated	Piper Sandler	Overweight	$48
Mar-27-25	Initiated	JP Morgan	Overweight

Aug-21-26 08:30AM	ASCENTAGE PHARMA GROUP INTERNATIONAL Q2 2026 Earnings Call Summary (Moby)
Aug-19-26 07:00PM	Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates (GlobeNewswire)
Aug-13-26 08:00AM	Ascentage Pharma to Participate in the Evercore 2nd Annual China Biotech Summit (GlobeNewswire)
Aug-05-26 09:07AM	CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026 (GlobeNewswire)
08:00AM	Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026 (GlobeNewswire)
07:30PM	Loading…
Aug-02-26 07:30PM	Ascentage Pharma Appoints Dr. Faical Miyara as Chief Business Officer and Jim Ziegler as Chief Commercial Officer (GlobeNewswire)
Jul-26-26 07:30PM	Ascentage Pharma Chairman and CEO Dr. Dajun Yang Named to The Medicine Maker Power List 2026 (GlobeNewswire)
Jun-14-26 07:30PM	Ascentage Pharma Presents Multiple Clinical Updates at EHA2026 Congress (GlobeNewswire)
May-31-26 07:30PM	Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026 (GlobeNewswire)
07:30PM	Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026 (GlobeNewswire)
07:30PM	Ascentage Pharma Presents Data on Olverembatinib in CML-LBP and Ph+ BCP-ALL at ASCO 2026 (GlobeNewswire)
May-21-26 08:00PM	Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026 (GlobeNewswire)
May-12-26 10:15PM	Ascentage Pharma to Present 17 Clinical Advances at 2026 European Hematology Association Congress (GlobeNewswire)
08:00AM	Ascentage Pharma to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Apr-21-26 08:00PM	Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026 (GlobeNewswire)
08:00PM	Loading…
Apr-19-26 08:00PM	Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting (GlobeNewswire)
Mar-25-26 07:00PM	Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates (GlobeNewswire)
Mar-17-26 08:00PM	Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026 (GlobeNewswire)
Mar-11-26 08:00AM	Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026 (GlobeNewswire)
Feb-23-26 08:00AM	Ascentage Pharma to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Feb-11-26 03:16PM	Rodman & Renshaw Initiates Ascentage Pharma Group International (AAPG) with Buy Rating, $48 Target (Insider Monkey)
Feb-09-26 08:00AM	Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Feb-06-26 06:13PM	Ascentage Pharma Receives Clearance from Chinas CDE for New Drug (Exec Edge)
Feb-05-26 06:30PM	Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 (GlobeNewswire)
Jan-14-26 08:25PM	Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
12:10AM	Ascentage: Partnership With Takeda Going Well (Bloomberg)
Jan-07-26 05:09PM	Ascentage Pharma B-Cell Cancer Candidate Receives FDA IND Clearance (Exec Edge) +8.50%
Jan-06-26 08:00PM	Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288 (GlobeNewswire)
Dec-17-25 08:00AM	Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-08-25 07:45PM	ASH 2025 Updated Data for Ascentage Pharma's Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment (GlobeNewswire)
07:45PM	Loading…
07:45PM	ASH 2025 Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP (GlobeNewswire)
07:45PM	ASH 2025 Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60% (GlobeNewswire)
Dec-07-25 08:10PM	ASH 2025 Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Exposed Patients with Myeloid Malignances (GlobeNewswire)
Dec-06-25 10:15AM	Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Dec-04-25 07:00PM	Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA (GlobeNewswire) +7.10%
07:27AM	An Arch-backed biotech raises $53M to fight neurodegeneration (BioPharma Dive)
Dec-01-25 08:00AM	Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025 (GlobeNewswire)
Nov-24-25 07:00PM	Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature's Signal Transduction and Targeted Therapy (GlobeNewswire)
Nov-19-25 08:00AM	Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025 (GlobeNewswire)
Nov-05-25 09:51AM	Pinterest downgraded, Tractor Supply upgraded: Wall Street's top analyst calls (The Fly)
Nov-03-25 08:10PM	Ascentage Pharma to Present Data from Two Clinical Studies for Bcl-2 Inhibitor Lisaftoclax, Including an Oral Report, at ASH 2025 (GlobeNewswire)
08:10PM	Ascentage Pharma to Present Data from Multiple Studies of Olverembatinib, Including the First Dataset from POLARIS-1 Study, at ASH 2025 (GlobeNewswire)
Oct-29-25 08:00PM	Ascentage Pharma to Participate in Two Upcoming Investor Conferences in November 2025 (GlobeNewswire)
Oct-07-25 08:00AM	Ascentage Pharma to Participate in Three Upcoming Investor Conferences in October 2025 (GlobeNewswire)
Sep-01-25 12:00PM	Ascentage Pharma Group International - Unsponsored ADR (AAPG) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:55AM	Here's Why Ascentage Pharma Group International - Unsponsored ADR (AAPG) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Aug-25-25 08:00AM	Ascentage Pharma to Participate in Three Upcoming Investor Conferences in September 2025 (GlobeNewswire) -9.23%
Aug-20-25 07:57PM	Ascentage Pharma Reports 2025 Interim Unaudited Six Months Financial Results and Business Updates (GlobeNewswire)
Aug-19-25 04:20PM	Ascentage Pharmas Lisaftoclax Gets FDA/EMA Clearance (Exec Edge)
Aug-17-25 07:30PM	Ascentage Pharma Announces Global Registrational Phase III Study of Lisaftoclax for First-line Treatment of Patients with Higher-Risk Myelodysplastic Syndrome Cleared by US FDA and EMA (GlobeNewswire)
Aug-07-25 08:00AM	Ascentage Pharma to Report 2025 Six Month Interim Results and Provide Corporate Update on August 20, 2025 (GlobeNewswire)
Aug-01-25 08:00AM	Ascentage Pharma to Participate in Evercore China Biotech Summit (GlobeNewswire)
Jul-23-25 08:00AM	Ascentage Pharma to Participate in BTIG Virtual Biotechnology Conference 2025 (GlobeNewswire)
Jul-21-25 12:14AM	Ascentage Pharma Raises $192.3M Through Oversubscribed Offshore Share Placement (Insider Monkey)
Jul-17-25 04:30AM	Ascentage Pharma Announces Closing of Placement Shares in Top-Up Placement (GlobeNewswire)
Jul-14-25 11:12AM	Ascentage Pharma's Novel Cancer Drug Approved in China (Insider Monkey) -5.33%
10:35AM	Ascentage Pharma Announces Pricing of Top-Up Placement (GlobeNewswire)
05:23AM	Ascentage Pharma Announces Proposed Top-Up Placement (GlobeNewswire)
Jul-10-25 12:55PM	Ascentage Pharma Announces NMPA Approval for Blood Cancer Drug (Exec Edge)
09:30AM	Ascentage Pharma Announces Its Novel Bcl-2 Inhibitor Lisaftoclax Approved by China NMPA, Ushering in a New Era for the Treatment of CLL/SLL (GlobeNewswire)
Jul-08-25 11:58AM	Ascentage Pharma Names CFO & SVP of Global Corporate Development & Finance (Exec Edge)
Jul-07-25 07:30PM	Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance (GlobeNewswire)
Jun-15-25 07:30PM	EHA 2025 Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL (GlobeNewswire)
Jun-09-25 07:30PM	Thirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress (GlobeNewswire) +5.29%
Jun-02-25 07:30PM	Live from ASCO 2025 Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors (GlobeNewswire) +10.03%
07:30PM	Live from ASCO 2025 Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report (GlobeNewswire)
May-22-25 08:15PM	Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025 (GlobeNewswire)
May-11-25 05:20PM	Is Ascentage Pharma (AAPG) the Best Performing Healthcare Stock to Buy Now? (Insider Monkey)
Apr-28-25 07:00AM	Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax (GlobeNewswire)
Apr-23-25 07:00PM	Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin (GlobeNewswire) +10.65% +6.69%
Apr-21-25 06:10PM	Ascentage Pharma Drugs Included in Chinese Society of Clinical Oncology Guidelines (Exec Edge) +12.97%
07:00AM	Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines (GlobeNewswire)
Apr-02-25 01:07PM	Stocks To Watch In Gloomy Market Including This Breakout IPO (Investor's Business Daily)
Mar-27-25 07:00AM	Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates (GlobeNewswire) +9.96%
Mar-25-25 07:00PM	Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire)
Mar-12-25 08:46AM	Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025 (GlobeNewswire)
Mar-06-25 05:18PM	Ascentage Secures Third Breakthrough Therapy for Ph+ ALL Treatment (Exec Edge)
Mar-05-25 06:00PM	Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) (GlobeNewswire)
Feb-07-25 08:24AM	Ascentage Pharma Announces Partial Exercise of Underwriters' Option to Purchase Additional American Depositary Shares (GlobeNewswire)
Jan-28-25 04:01PM	Ascentage Pharma Announces Closing of U.S. Initial Public Offering (GlobeNewswire)

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

Ph.D.Dr. Dajun Yang M.D.

Co-FounderDr. Shaomeng Wang Ph.D.

Co-FounderDr. Ming Guo Ph.D.

Chief Financial OfficerDr. Veet Misra

Senior Director of Investor RelationsYuly Chen

Insider Trading	Relationship	Date	Transaction	#Shares	#Shares Total	SEC Form 4
Zhai Yifan	Chief Medical Officer	May 21 '26	Option Exercise	95,575	1,193,569	May 22 04:44 PM
Zhai Yifan	Chief Medical Officer	May 21 '26	Option Exercise	92,746	405,280	May 22 04:44 PM
Yang Dajun	Chairman and CEO	May 21 '26	Option Exercise	92,746	405,280	May 22 04:18 PM
Yang Dajun	Chairman and CEO	May 21 '26	Option Exercise	95,575	1,193,569	May 22 04:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AAPG

Ascentage Pharma Group International ADR

Upgrade your Finviz experience